Ratings Apeloa Pharmaceutical Co.,Ltd

Equities

000739

CNE000000Q45

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-19 pm EDT			5-day change	1st Jan Change
15.66 ^CNY	+0.71%		+2.02%	+1.75%

Apr. 17	Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 10	Apeloa Pharmaceutical Co.,Ltd Approves Cash Dividend for 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

Analysts covering this company mostly recommend stock overweighting or purchase.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The valuation of the company is particularly high given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
APELOA PHARMACEUTICAL CO.,LTD	+1.75%	2.52B	D+
ELI LILLY AND COMPANY	+34.35%	693B	C+
NOVO NORDISK A/S	+29.39%	584B	B
JOHNSON & JOHNSON	-3.49%	372B	C+
MERCK & CO., INC.	+20.15%	332B	B-
ABBVIE INC.	+6.19%	294B	C+
ASTRAZENECA PLC	+14.11%	239B	B+
ROCHE HOLDING AG	-3.03%	211B	A+
NOVARTIS AG	+10.02%	210B	B-
AMGEN INC.	+9.21%	168B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes